Evidence map›Paper›PMID 31174057›Full record

ArticleTranslational oncology2019

Characterization of Novel Murine and Human PDAC Cell Models: Identifying the Role of Intestine Specific Homeobox Gene ISX in Hypoxia and Disease Progression.

Arsheed A Ganaie, Aijaz Parray, Tabish Hussain, Ashraf Shabaneh, Anmbreen Jamroze, Marina G Ferrari, Lei Wang, D Joshua Liao, Shahriar Koochekpour, Sanjeev Nanda and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Arsheed A GanaieDepartment of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Aijaz ParrayDepartment of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Translational Research Institute, Academic Health Systems Hamad Medical Corporation, Doha, Qatar.
Tabish HussainDepartment of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; MD Anderson Cancer Center, Science Park, Smithville, TX.
Ashraf ShabanehInstitute for Health Informatics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Anmbreen JamrozeHormel Institute, University of Minnesota, Austin, MN.
Marina G FerrariDepartment of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Lei WangDepartment of Cancer Genetics, Hormel Institute, University of Minnesota, Austin, MN.
D Joshua LiaoDepartment of Cancer Genetics, Hormel Institute, University of Minnesota, Austin, MN.
Shahriar KoochekpourDepartment of Urology, University of Florida, Jacksonville, Florida.
Sanjeev NandaDepartment of General Internal Medicine, Mayo Clinic, Rochester, MN.
Jinhua WangInstitute for Health Informatics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Yibin DengDepartment of Cancer Genetics, Hormel Institute, University of Minnesota, Austin, MN.
Sergio A GradiloneCancer Cell Biology and Translational Research Section, Hormel Institute, University of Minnesota, Austin, MN.
Edward H HinchcliffeCellular Dynamics Section, The Hormel Institute, University of Minnesota.
Badrinath R KonetyDepartment of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Mohammad SaleemDepartment of Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN. Electronic address: msbhat@umn.edu.
University of Minnesota · USUniversity of Minnesota Medical Center · USCancer Genetics (United States) · USHamad Medical Corporation · QAHormel (United States) · USUniversity of Florida · USWinnMed · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Novel targeted chemo/immunotherapy approach for localized and metastatic CaPR01CA193739 · NCI · UNIVERSITY OF MINNESOTA · PI BHAT, MOHAMMAD SALEEM · 2016 to 2020
$1.8M
The Cholangiocyte Primary Cilium as a Tumor Suppressor OrganelleR01CA183764 · NCI · UNIVERSITY OF MINNESOTA · PI GRADILONE, SERGIO A · 2015 to 2019
$1.7M
Novel gene that determines metastatic phenotype in African-American men with PCaR21CA184685 · NCI · UNIVERSITY OF MINNESOTA · PI BHAT, MOHAMMAD SALEEM · 2015 to 2016
$582k
NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA183764NCI NIH HHS R01 CA193739NCI NIH HHS R21 CA184685
6 · The paper itself

Abstract

Therapy failure and metastasis-associated mortality are stumbling blocks in the management of PDAC in patients. Failure of therapy is associated to intense hypoxic conditions of tumors. To develop effective therapies, a complete understanding of hypoxia-associated changes in genetic landscape of tumors during disease progression is needed. Because artificially immortalized cell lines do not rightly represent the disease progression, studying genetics of tumors in spontaneous models is warranted. In the current study, we generated a spectrum of spontaneous human (UM-PDC1; UM-PDC2) and murine (HI-PanL, HI-PancI, HI-PanM) models representing localized, invasive, and metastatic PDAC from a patient and transgenic mice (K-ras

Identifiers

PMID31174057
PMCPMC6556561
OpenAlexW2948868443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.